Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1198 • ACR Convergence 2021
Ultrasonography of the Median Nerve in Patients with Rheumatoid Arthritis Under Suspicion of Carpal Tunnel Syndrome
Styliani Tsiami¹, Efthymia Ntasiou², Christos Krogias², Ralf Gold², Jürgen Braun¹, Michael Sarholz³ and Xenofon Baraliakos¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Josef-Hospital, Bochum and Ruhr-University Bochum, Germany, Bochum, Germany, ³Klinik fuer Rheumatologie, St. Marien-Hospital Vreden, Vreden, Germany
Background/Purpose: Carpal tunnel syndrome (CTS) is the most common nerve compression syndrome and a common extra-articular manifestation of rheumatoid arthritis (RA). Different causes of CTS…
Abstract Number: 1214 • ACR Convergence 2021
Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis
Kristin Wipfler¹, Joshua Baker², Harlan Sayles³, Xue Han⁴, Sang Hee Park⁴, Keith Wittstock⁴, Ted Mikuls³ and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…
Abstract Number: 1230 • ACR Convergence 2021
Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Jeffrey Sparks², Arnaud Constantin³, Ricardo Xavier⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Toulouse University Hospital, Toulouse Cedex 9, France, ⁴Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵AbbVie Inc., North Chicago, IL, ⁶University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
Abstract Number: 1246 • ACR Convergence 2021
The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients
Devy Zisman¹, Mirna Safieh¹, Elina Simanovich¹, Joy Feld², Amalia Kinarty¹, Liron Zisman¹, Tal Gazitt³, Amir Haddad⁴, Muna Elias¹, Itzhak Rosner⁵, Lisa Kaly⁶ and Michal A Rahat⁷, ¹Carmel Medical Center, Haifa, Israel, ²Carmel and Zvulun Medical Centre, Haifa, Israel, ³Carmel Hospital, Haifa, Israel, ⁴Carmel Medical Centre, Haifa, Israel, ⁵Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ⁶Bnei Zion Medical Center, Haifa, Israel, ⁷Carmel Medical Center/Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Background/Purpose: Angiogenesis is an important contributor to the development of rheumatoid arthritis (RA). Tocilizumab (TCZ), an anti-IL-6 receptor antibody used in the treatment of RA…
Abstract Number: 1443 • ACR Convergence 2021
Long-term Effectiveness of Ultra-Low Doses of Rituximab in Rheumatoid Arthritis
Nathan den Broeder¹, Lise Verhoef², Yael De Man³, Marc Kok⁴, Rogier Thurlings⁵, Wilfred van der Weele⁶, Bart van den Bemt⁷, Frank van den Hoogen⁸, Aatke van der Maas⁹ and Alfons den Broeder¹⁰, ¹Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Ziekenhuisgroep Twente (Hospital Group Twente), Borne, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Reade, Amsterdam, Netherlands, ⁷Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁸Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁹St Maartenskliniek, Nijmegen, Gelderland, Netherlands, ¹⁰Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: The optimal rituximab (RTX) dose for the treatment of rheumatoid arthritis remains unclear. RTX treatment of 1000mg per 6 months and 2000mg per 6…
Abstract Number: 1603 • ACR Convergence 2021
COVID-19 Vaccination Experience in Patients with Rheumatoid Arthritis Treated at the Cleveland VA Medical Center
Sarah Abi Doumeth¹, Laura Silversteyn², Donald Anthony² and Maya Mattar³, ¹University hospitals Cleveland medical center, Cleveland, OH, ²Louis Stokes Cleveland VA Medical Center, Cleveland, OH, ³Louis Stokes VA Medical Center, Mayfield Heights, OH
Background/Purpose: Following the introduction of the COVID-19 vaccines, there has been uncertainty as to whether receiving the COVID-19 vaccine would result in overactivation of the…
Abstract Number: 1661 • ACR Convergence 2021
Sex-Stratified Patterns of Multimorbidity at RA Onset and Associated Longitudinal Impacts on Disability Over the First Year Follow Up: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Susan Bartlett², Marie-France Valois², Louis Bessette³, Gilles Boire⁴, Glen Hazlewood⁵, Edward Keystone⁶, Janet Pope⁷, Carter Thorne⁸, Diane Tin⁸ and Vivian Bykerk⁹, ¹Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Chronic disease multimorbidity (MM) is prevalent in RA. As MM can vary in complexity and different combinations of chronic conditions may have different physical…
Abstract Number: 1677 • ACR Convergence 2021
Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis
Yusuke Miwa¹ and Yuko Mitamura², ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: Rheumatoid arthritis (RA) and dyslipidemia are associated with inflammation. Although the low-density lipoprotein cholesterol (LDL-C) is normal range, the high-density lipoprotein cholesterol (HDL-C) is…
Abstract Number: 1693 • ACR Convergence 2021
Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study
Christof Specker¹, Martin Aringer², Gerd Burmester³, Marvin A. Peters⁴, Michael W. Hofmann⁵, Herbert Kellner⁶, Frank Moosig⁷, Hans-Peter Tony⁸ and Gerhard Fliedner⁹, ¹Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Chugai Pharma Germany GmbH, Frankfurt am Main, Germany, ⁶Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany, ⁷Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, ⁸Universitätsklinikum Würzburg, Wuerzburg, Germany, ⁹Rheumatology Practice, Osnabrueck, Germany
Background/Purpose: To limit the risk of serious infections, guidelines recommend short term (< 3 months) or low-dose (≤10 mg/day) adjunct glucocorticoids (GCs) to control rheumatoid…
Abstract Number: 1710 • ACR Convergence 2021
Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
Daniel Aletaha¹, Rene Westhovens², Tatsuya Atsumi³, YingMeei Tan⁴, Alena Pechonkina⁵, Qi Gong⁵, Vijay Rajendran⁶, Sander Strengholt⁷ and Gerd Burmester⁸, ¹Medical University Vienna, Vienna, Austria, ²University Hospitals KU Leuven, Maaseik, Belgium, ³Hokkaido University, Sapporo, Japan, ⁴Gilead Sciences, Inc, San Diego, CA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos, BV, New York, NY, ⁸Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. In this…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: 0023 • ACR Convergence 2021
Investigating Temporal Changes in Pregnancy Among Women with Rheumatoid Arthritis and Healthy Women Using Co-expression Network Analysis
Matthew Wright¹, Dana Goin², Mette Smed³, J Lee Nelson⁴, Nicholas Jewell⁵, Jorn Olsen⁶, Merete Hetland⁷, Vibeke Zoffmann³ and Damini Jawaheer⁸, ¹UCSF Benioff Children's Hospital Oakland, Oakland, CA, ²University of California San Francisco, San Francisco, CA, ³Juliane Marie Center, Rigshospitalet, Copenhagen, Denmark, ⁴Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, ⁵University of California Berkeley, Berkeley, CA, ⁶Aarhus University Hospital, Aarhus, Denmark, ⁷DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁸UCSF Benioff Children's Hospital Oakland / University of California San Francisco, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA), while still an incurable disease, can often improve naturally during pregnancy. The specific mechanism(s) underlying this pregnancy-induced improvement, however, are not…
Abstract Number: 0039 • ACR Convergence 2021
Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?
Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…
Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Joseph Couto¹, Elisea Avalos-Reyes², Amanda McCarthy³, Olga Matlin⁴, Michele Hamburger⁵, Gerard Maher⁶ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Irving, TX, ³CVS Health, Greensboro, GA, ⁴CVS Health, Northbrook, IL, ⁵Frances Hamburger Institute, Hauppauge, NY, ⁶Frances Hamburger Institute, Hauppaugue, NY
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…
Abstract Number: 0200 • ACR Convergence 2021
In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes
Marloes Verstappen, Xanthe Matthijssen and Annette H.M van der Helm-van Mil, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: International guidelines stress timely DMARD-initiation in early arthritis, also when classification-criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA)-patients are increasingly treated despite placebo-controlled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].